WO2008070448A3 - Cancer-specific promoters - Google Patents

Cancer-specific promoters Download PDF

Info

Publication number
WO2008070448A3
WO2008070448A3 PCT/US2007/085223 US2007085223W WO2008070448A3 WO 2008070448 A3 WO2008070448 A3 WO 2008070448A3 US 2007085223 W US2007085223 W US 2007085223W WO 2008070448 A3 WO2008070448 A3 WO 2008070448A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific
cancer
combination
sequences
sequence
Prior art date
Application number
PCT/US2007/085223
Other languages
French (fr)
Other versions
WO2008070448A2 (en
Inventor
Mien-Chie Hung
Xiaoming Xie
Jing-Yu Lang
Original Assignee
Univ Texas
Mien-Chie Hung
Xiaoming Xie
Jing-Yu Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Mien-Chie Hung, Xiaoming Xie, Jing-Yu Lang filed Critical Univ Texas
Publication of WO2008070448A2 publication Critical patent/WO2008070448A2/en
Publication of WO2008070448A3 publication Critical patent/WO2008070448A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly in combination with a two-step transcription amplification sequence and/or a post-transcriptional control sequence. Two ovarian cancer-specific sequences utilize specific regions of hTERT and survivin promoters, particularly in combination with a two-step transcription amplification sequence and/or a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
PCT/US2007/085223 2006-11-22 2007-11-20 Cancer-specific promoters WO2008070448A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86074506P 2006-11-22 2006-11-22
US60/860,745 2006-11-22

Publications (2)

Publication Number Publication Date
WO2008070448A2 WO2008070448A2 (en) 2008-06-12
WO2008070448A3 true WO2008070448A3 (en) 2008-12-18

Family

ID=39492966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085223 WO2008070448A2 (en) 2006-11-22 2007-11-20 Cancer-specific promoters

Country Status (2)

Country Link
US (1) US20090192101A1 (en)
WO (1) WO2008070448A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515532A (en) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ， リミテッド MIR-21 promoter driven target cancer treatment
WO2011022633A2 (en) 2009-08-21 2011-02-24 Smithkline Beecham (Cork) Ltd. Method of threating cancer
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
CN104039343A (en) * 2011-06-06 2014-09-10 罗得岛州妇婴医院 He4 based therapy for malignant disease
CA3113325A1 (en) 2018-10-11 2020-04-16 Eidgenossische Technische Hochschule Zurich A method to treat disease using a nucleic acid vector encoding a highly compact multi-input logic gate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103251A2 (en) * 2004-04-02 2005-11-03 Board Of Regents, The University Of Texas System Cancer specific promoters

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6716824B1 (en) * 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
EP1207204A1 (en) * 2000-11-16 2002-05-22 KWS Saat AG Tissue-specific promoters from sugar beet
WO2004089981A2 (en) * 2003-04-02 2004-10-21 Board Of Regents, The University Of Texas System Antitumor effect of mutant bik

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103251A2 (en) * 2004-04-02 2005-11-03 Board Of Regents, The University Of Texas System Cancer specific promoters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHALBOS D ET AL: "FATTY ACID SYNTHETASE AND ITS MESSENGER RNA ARE INDUCED BY PROGESTINS IN BREAST CANCER CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 21, 1987, pages 9923 - 9926, XP009103100, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008070448A2 (en) 2008-06-12
US20090192101A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2005103251A3 (en) Cancer specific promoters
WO2008070448A3 (en) Cancer-specific promoters
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2016106401A3 (en) Rna agents for p21 gene modulation
WO2010065792A3 (en) Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2285989A4 (en) Novel targets for regulation of angiogenesis
TN2012000188A1 (en) Novel antitumoral use of cabazitaxel
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
WO2007147409A3 (en) Ribozyme mediated stabilization of polynucleotides
MX2010006039A (en) Rna antagonist compounds for the modulation of pik3ca expression.
MX2011012505A (en) Substituted piperidines.
WO2013177248A3 (en) Modulation of enhancer rna mediated gene expression
WO2010007522A8 (en) Rna antagonists targeting gli2
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
EP4276184A3 (en) Pharmaceutical composition comprising mirna-3140 for use in treating cancer
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2008118792A3 (en) Gamma delta t cells and methods of treatment of interleukin-17 related conditions
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
WO2012078586A3 (en) Pharmaceutical composition comprising nanog shrna, and method of usnig nanog shrna to treat cancer
WO2013103836A3 (en) Methods of treating cancer
WO2011040613A8 (en) Therapeutic agent for tumor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871536

Country of ref document: EP

Kind code of ref document: A2